#USA #Anixa Biosciences #San Jose #CAR-T therapy #Moffitt Cancer Center

Anixa Biosciences Advances CAR-T Clinical Trial for Ovarian Cancer

Anixa Biosciences, a biotechnology firm listed on NASDAQ as ANIX, has recently announced the successful dosing of its final patient in the third cohort of a crucial Phase 1 clinical trial targeting recurrent ovarian cancer. This significant milestone reflects the company’s commitment to enhancing treatment strategies for this challenging condition, in partnership with the Moffitt Cancer Center.

Understanding the CAR-T Trial

The trial under examination utilizes a novel CAR-T (chimeric antigen receptor T-cell) therapy developed by Anixa. Particularly, this therapy leverages the follicle-stimulating hormone receptor (FSHR), which is found exclusively on ovarian cells and specific cancerous tissues. This targeted approach aims to selectively attack ovarian cancer cells while minimizing damage to healthy cells, a common challenge faced in conventional cancer treatments.

The third cohort of this ongoing trial involved administering one million CAR-positive cells per kilogram of patient body weight. This represents a tenfold increase in dosage compared to previous cohorts, underscoring Anixa's strategy of carefully escalating dosages to both assess efficacy and ensure patient safety.

Next Steps in the Clinical Trial

Looking ahead, the fourth cohort is anticipated to commence following a 30-day observation period to confirm the absence of any adverse effects experienced by participants of the third cohort. The research team plans to increase the dosage further by a factor of three, a move that highlights their ongoing efforts to optimize treatment efficacy.

Chairman and CEO Dr. Amit Kumar expressed optimism regarding the insights gained from the completion of the third cohort. He emphasized that increasing the dosage is vital for evaluating the treatment's effectiveness while ensuring that patient safety remains a priority. Furthermore, the recent approval of a protocol amendment allows participants who might benefit to receive a second dose—an addition supported by broadened enrollment criteria which encompass rarer ovarian cancer subtypes. This change is crucial as it enhances accessibility to treatment options for a greater number of patients.

Anixa’s Broader Vision in Cancer Treatment

As a clinical-stage biotechnology company, Anixa is devoted to innovating therapies that prevent and treat cancer. Its CAR-T program for ovarian cancer is just one facet of a larger portfolio that includes immunotherapy options partnered with esteemed institutions like the Cleveland Clinic, targeting both breast and ovarian cancers, amongst others. Such collaborations enable Anixa to continually explore new treatments and advancements in cancer care.

The overarching goal remains to deliver effective therapies that provide new hope for patients battling recurrent ovarian cancer, with a keen focus on both immediate and long-term outcomes.

For ongoing updates regarding Anixa's clinical trials and their quest to enhance cancer treatment methodologies, interested individuals can visit their official website at www.anixa.com or follow them on various social media platforms.

In conclusion, as Anixa Biosciences progresses through its clinical trials, it stands at the forefront of innovative cancer therapies, aiming to transform the landscape of treatment options available to patients struggling with ovarian cancer.